Home › Certara's Synchrogenix Division Provides Unique Technology Solution, Enabling Biopharma Companies To Comply With EMA Policy 70
 

Keywords :   


Certara's Synchrogenix Division Provides Unique Technology Solution, Enabling Biopharma Companies To Comply With EMA Policy 70

2016-03-30 06:49:06| drugdiscoveryonline Home Page

Certara, the global biosimulation technology-enabled drug development company, recently announced that its regulatory and medical consultancy, Synchrogenix, has introduced an artificial intelligence (AI) -enabled solution to meet the data transparency requirements of the clinical and drug development market

Tags: policy technology unique companies

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
15.05Indian spices face heat over global safety concerns
15.05'Corrupt ship inspectors demand our food and cargo'
15.05Taylor Swift Eras Tour to boost UK spending by 1bn, says report
15.05Three ways to win the rental property race
15.05Renters in scrum for homes as listing time slashed
14.05Nu Skin Releases 2023 Social Impact and Sustainability Report
14.05P&G Unveils Plans to Feature Brands During the Olympic and Paralympic Games Paris 2024
14.05The LOccitane Group Appoints Evelyne LY-Wainer Managing Director Global Travel Retail
More »